Liver transplantation is a life-saving procedure for patients with end-stage liver disease. Risk of post-transplantation infection remains high despite improvement in graft and patient survival. Antibacterial and antifungal prophylaxis plays an important role in reducing infection-related morbidity and mortality, but optimal timing and regimens are not well defined.
Methods:
The Surgical Infection Society’s (SIS) Therapeutics and Guidelines Committee and individuals with content expertise convened to develop guidelines on antibacterial and antifungal prophylaxis in liver transplant to prevent surgical site infection and other infections, shorten intensive care unit length of stay, and decrease mortality. PubMed, Embase, Web of Science, and the Cochrane Database were searched using Medical Subject Heading terms including “liver transplantation,” “antibiotic prophylaxis,” and “antifungal prophylaxis” for studies limited to randomized controlled trials, systematic reviews, meta-analyses, cohort, and case–control studies in adult patients. Evaluation of the published evidence was performed using the Grading of Recommendations Assessment, Development and Evaluation system, and final recommendations were developed by an iterative process.
Results:
We cannot make a recommendation for or against using pre-operative (more than 1 h before incision) antibiotic agent prophylaxis in liver transplantation with available evidence. We suggest the use of broad-spectrum antibiotic agent prophylaxis in liver transplantation rather than gram-positive antibiotic agent prophylaxis alone (Grade 2B). We recommend limiting administration of antibiotic agent prophylaxis to 24 hours post-operatively after liver transplant (Grade 1B). We recommend against empiric antifungal prophylaxis for patients at low risk for invasive fungal infections (IFIs) after liver transplant; for patients at high risk for IFI, we recommend antifungal prophylaxis (Grade 1B).
Conclusions:
This guideline summarizes the current SIS recommendations on antibacterial and antifungal prophylaxis in liver transplantation.
KwongAJ, KimWR, LakeJR, et al.OPTN/SRTR 2023 annual data report: Liver. Am J Transplant2025;25(2S1):S193–S287; doi: 10.1016/j.ajt.2025.01.022
2.
van DeldenC, StampfS, HirschHH, Swiss Transplant Cohort Study. et al.; Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study. Clin Infect Dis2020;71(7):e159–e169; doi: 10.1093/cid/ciz1113
3.
Leibovici-WeissmanY, AnchelN, NesherE, et al.Early post-liver transplantation infections and their effect on long-term survival. Transpl Infect Dis2021;23(4):e13673; doi: 10.1111/tid.13673
4.
BaganateF, BealEW, TuminD, et al.Early mortality after liver transplantation: Defining the course and the cause. Surgery2018;164(4):694–704; doi: 10.1016/j.surg.2018.04.039
5.
FreireMP, SongATW, OshiroICV, et al.Surgical site infection after liver transplantation in the era of multidrug-resistant bacteria: What new risks should be considered? Diagn Microbiol Infect Dis2021;99(1):115220; doi: 10.1016/j.diagmicrobio.2020.115220
6.
FischerSA, LuK, AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant2013;13(Suppl 4):9–21; doi: 10.1111/ajt.12094
7.
GeorgeDL, ArnowPM, FoxAS, et al.Bacterial infection as a complication of liver transplantation: Epidemiology and risk factors. Rev Infect Dis1991;13(3):387–396.
8.
AsensioA, RamosA, Cuervas-MonsV, Red de Estudio de la Infección en el Trasplante—Grupo de Estudio de la Infección en el Trasplante. et al.; Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl2008;14(6):799–805; doi: 10.1002/lt.21435
9.
Van HoekB, De RooijBJ, VerspagetHW. Risk factors for infection after liver transplantation. Best Pract Res Clin Gastroenterol2012;26(1):61–72; doi: 10.1016/j.bpg.2012.01.004
10.
ViehmanJA, ClancyCJ, ClarkeL, et al.Surgical site infections after liver transplantation: Emergence of multidrug-resistant bacteria and implications for prophylaxis and treatment strategies. Transplantation2016;100(10):2107–2114; doi: 10.1097/TP.0000000000001356
11.
BratzlerDW, DellingerEP, OlsenKM, Society for Healthcare Epidemiology of America. et al.; Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm2013;70(3):195–283; doi: 10.2146/ajhp120568
12.
AbboLM, GrossiPA, the AST ID Community of Practice. Surgical site infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant2019;33(9):e13589; doi: 10.1111/ctr.13589
13.
ArkseyH, O’MalleyL. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol2005;8(1):19–32; doi: 10.1080/1364557032000119616
14.
ChenY, YangK, MarušicA, RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. et al.; A reporting tool for practice guidelines in health care: The RIGHT statement. Ann Intern Med2017;166(2):128–132; doi: 10.7326/M16-1565
15.
XingT, ZhongL, PengZ. Safety and effectiveness of antifungal prophylaxis in preventing fungal infection after liver transplantation: A meta-analysis of randomized clinical trials. Int J Clin Pharmacol Ther2016;54(8):564–571; doi: 10.5414/CP202255
16.
PlayfordEG, WebsterAC, CraigJC, et al.Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Kidney and Transplant Group, ed. Cochrane Database Syst Rev2004;2004(3):CD004291; doi: 10.1002/14651858.CD004291.pub2
17.
PlayfordEG, WebsterAC, SorrellTC, et al.Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis2006;25(9):549–561; doi: 10.1007/s10096-006-0182-3
18.
LiuY, LanC, QinS, et al.Efficacy of anti‐fungal agents for invasive fungal infection prophylaxis in liver transplant recipients: A network meta‐analysis. Mycoses2022;65(10):906–917; doi: 10.1111/myc.13508
19.
GattiM, RinaldiM, FerraroG, et al.Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta‐analysis. Mycoses2021;64(11):1317–1327; doi: 10.1111/myc.13362
20.
EvansJDW, MorrisPJ, KnightSR. Antifungal prophylaxis in liver transplantation: A systematic review and network meta-analysis. Am J Transplant2014;14(12):2765–2776; doi: 10.1111/ajt.12925
21.
CrucianiM, MengoliC, MalenaM, et al.Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis. Liver Transpl2006;12(5):850–858; doi: 10.1002/lt.20690
22.
Campos‐VarelaI, BlumbergEA, GiorgioP, et al.What is the optimal antimicrobial prophylaxis to prevent postoperative infectious complications after liver transplantation? A systematic review of the literature and expert panel recommendations. Clin Transplant2022;36(10):e14631; doi: 10.1111/ctr.14631
23.
BiancofioreG, BindiML, BaldassarriR, et al.Antifungal prophylaxis in liver transplant recipients: A randomized placebo-controlled study. Transpl Int2002;15(7):341–347; doi: 10.1007/s00147-002-0431-z
24.
WinstonDJ, PakrasiA, BusuttilRW. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial. Ann Intern Med1999;131(10):729–737; doi: 10.7326/0003-4819-131-10-199911160-00003
25.
TollemarJ, HöckerstedtK, EriczonBG, et al.Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation1995;59(1):45–50; doi: 10.1097/00007890-199501150-00009
26.
SharpeMD, GhentC, GrantD, et al.Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: A prospective, randomized, double-blind study. Transplantation2003;76(6):977–983; doi: 10.1097/01.TP.0000085653.11565.52
27.
BandaliA, BiasTE, LeeDH, et al.Duration of perioperative antimicrobial prophylaxis in orthotopic liver transplantation patients. Prog Transplant2020;30(3):265–270; doi: 10.1177/1526924820933824
28.
EschenauerGA, KwakEJ, HumarA, et al.Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant2015;15(1):180–189; doi: 10.1111/ajt.12993
29.
San-JuanR, AguadoJM, LumbrerasC, RESITRA-REIPI Network, Spain. et al.; Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation2011;92(3):346–350; doi: 10.1097/TP.0b013e3182247bb4
30.
García PradoME, MatiaEC, CiuroFP, et al.Surgical site infection in liver transplant recipients: Impact of the type of perioperative prophylaxis. Transplantation2008;85(12):1849–1854; doi: 10.1097/TP.0b013e3181735407
31.
GuyattGH, OxmanAD, VistGE, GRADE Working Group. et al.; GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924–926; doi: 10.1136/bmj.39489.470347.AD
32.
AndrewsJ, GuyattG, OxmanAD, et al.GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. J Clin Epidemiol2013;66(7):719–725; doi: 10.1016/j.jclinepi.2012.03.013
33.
GuyattG, OxmanAD, AklEA, et al.GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol2011;64(4):383–394; doi: 10.1016/j.jclinepi.2010.04.026
34.
ShafiekhaniM, KarimzadehI, NikeghbalianS, et al.Comparison of ceftizoxime plus ampicillin-sulbactam versus gentamicin plus ampicillin-sulbactam in the prevention of post-transplant early bacterial infections in liver transplant recipients: A randomized controlled trial. Infect Drug Resist2020;13:89–98; doi: 10.2147/IDR.S222934
35.
BerryPS, RosenbergerLH, GuidryCA, et al.Intraoperative versus extended antibiotic prophylaxis in liver transplant surgery: A randomized controlled pilot trial. Liver Transpl2019;25(7):1043–1053; doi: 10.1002/lt.25486
36.
MullaneKM, DubberkeER, Practice on behalf of the AIC of. Management of Clostridioides (formerly Clostridium) Difficile Infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant2019;33(9):e13564; doi: 10.1111/ctr.13564
37.
AmjadW, QureshiW, MalikA, et al.The outcomes of Clostridioides difficile infection in inpatient liver transplant population. Transpl Infect Dis2022;24(1):e13750; doi: 10.1111/tid.13750
38.
DolciG, BurasteroGJ, PagliaF, et al.Epidemiology and prevention of early infections by multi-drug-resistant organisms in adults undergoing liver transplant: A narrative review. Microorganisms2023;11(6):1606; doi: 10.3390/microorganisms11061606
39.
Martin-MateosR, Martínez-ArenasL, Carvalho-GomesÁ, et al.Multidrug-resistant bacterial infections after liver transplantation: Prevalence, impact, and risk factors. J Hepatol2024;80(6):904–912; doi: 10.1016/j.jhep.2024.02.023
40.
PouchSM, PatelG, the AST Infectious Diseases Community of Practice. Multidrug‐resistant Gram‐negative bacterial infections in solid organ transplant recipients—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant2019;33(9):e13594; doi: 10.1111/ctr.13594
41.
ElbazA, PesquetC, DefayeM, et al.Perioperative antibiotic strategies in liver transplantation: A propensity score analysis of prophylaxis versus preemptive therapy. Transplantation2025;109(11):e647–e655; doi: 10.1097/TP.0000000000005442
42.
PappasPG, SilveiraFP, AST Infectious Diseases Community of Practice. Candida in solid organ transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg2009;9 Suppl 4:S173–S179; doi: 10.1111/j.1600-6143.2009.02909.x
43.
BajajJS, LiuEJ, KheradmanR, et al.Fungal dysbiosis in cirrhosis. Gut2018;67(6):1146–1154; doi: 10.1136/gutjnl-2016-313170
44.
GiannellaM, BartolettiM, MorelliMC, et al.Risk factors for infection with carbapenem-resistant klebsiella pneumoniae after liver transplantation: The importance of pre- and posttransplant colonization. Am J Transplant2015;15(6):1708–1715; doi: 10.1111/ajt.13136
45.
AlbillosA, Martin-MateosR, Van der MerweS, et al.Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol2022;19(2):112–134; doi: 10.1038/s41575-021-00520-7
46.
ZhangW, ChenY, ZhangY, et al.Carbapenems versus cephalosporin or piperacillin-tazobactam as perioperative antibiotic prophylaxis in liver transplant recipients with model for end-stage liver disease scores of ≥30: A retrospective study in a Chinese population. Infect Drug Resist2022;15:4487–4494; doi: 10.2147/IDR.S373773
47.
GavaldàJ, MeijeY, FortúnJ, ESCMID Study Group for Infections in Compromised Hosts. et al.; Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect2014;20 Suppl 7(s7):27–48; doi: 10.1111/1469-0691.12660
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
